(Q37947221)

25 August 2017

title

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus (English)

1 reference

methicillin-resistant Staphylococcus aureus

25 August 2017

main subject

0 references

Staphylococcus aureus

1 reference

Margaret R Jorgenson

1

1 reference

25 August 2017

Daryl D DePestel

series ordinal

2

1 reference

25 August 2017

Peggy L Carver

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

18 October 2011

1 reference

Annals of Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

45

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1384-1398

1 reference

The changing epidemiology of Staphylococcus aureus?

25 August 2017

cites work

1 reference

Community-acquired methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

New antimicrobial agents as therapy for resistant gram-positive cocci

21 January 2018

1 reference

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

Ceftaroline: a cephalosporin with expanded Gram-positive activity

21 January 2018

1 reference

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008.

21 January 2018

1 reference

In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.

21 January 2018

1 reference

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

21 January 2018

1 reference

Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia

21 January 2018

1 reference

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

21 January 2018

1 reference

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae

21 January 2018

1 reference

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

21 January 2018

1 reference

In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing

21 January 2018

1 reference

In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria

21 January 2018

1 reference

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates

21 January 2018

1 reference

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model.

21 January 2018

1 reference

Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection

21 January 2018

1 reference

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

21 January 2018

1 reference

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

21 January 2018

1 reference

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

21 January 2018

1 reference

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia

21 January 2018

1 reference

Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

Cephalosporin use in treatment of patients with penicillin allergies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q225

1 reference

25 August 2017

1 reference